Does Medicare Cover Mounjaro for Type 2 Diabetes in 2026? Coverage Rules, Costs, and What Most Patients Don't Know

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Medicare Part D covers Mounjaro (tirzepatide) for type 2 diabetes only, not for weight loss, and requires prior authorization in 94% of plans
• Typical out-of-pocket costs range from $280 to $650 per month depending on your plan's phase (deductible, initial coverage, or coverage gap)
• The Lilly savings card that reduces commercial insurance copays to $25 does NOT work for Medicare beneficiaries due to federal anti-kickback laws
• Approximately 42% of initial Medicare prior authorization requests for Mounjaro are denied, most commonly for insufficient documentation of metformin failure

Direct answer (40-60 words)

Yes, Medicare Part D covers Mounjaro for type 2 diabetes management in 2026, but not for weight loss. Coverage requires prior authorization in nearly all plans, proving you've tried and failed metformin or other first-line therapies. Monthly costs typically range from $280 to $650 depending on your plan phase and formulary tier. The manufacturer savings card doesn't apply to Medicare.

Table of contents

1. The 30-second answer
2. What most articles get wrong about Medicare and GLP-1 coverage
3. How Medicare Part D actually covers Mounjaro (the three-tier system)
4. Real cost scenarios across five common Part D plans
5. The prior authorization maze: what Medicare requires before approval
6. Why 42% of first-time requests get denied
7. The coverage gap (donut hole) and what it means for your Mounjaro cost
8. The Lilly savings card: why Medicare patients can't use it
9. Medicare Advantage vs Original Medicare: which covers Mounjaro better
10. The compounded tirzepatide alternative for Medicare patients
11. How to verify your specific plan's coverage in 10 minutes
12. When Medicare denies coverage: the three-step appeal process
13. FAQ
14. Sources

The 30-second answer

Medicare Part D plans cover Mounjaro when prescribed for type 2 diabetes. The medication sits on Tier 3 (preferred brand) or Tier 4 (specialty) in most formularies. You'll need prior authorization proving medical necessity. Expect to pay $280 to $650 per month depending on whether you're in your deductible phase, initial coverage period, or coverage gap. The Lilly savings card that helps commercial insurance patients doesn't work for Medicare due to federal law.

What most articles get wrong about Medicare and GLP-1 coverage

The most common error in published Medicare coverage guides is the claim that "Medicare doesn't cover weight-loss drugs." This statement is simultaneously true and misleading.

Here's what actually happens: Medicare Part D plans cover Mounjaro when the prescription is written for type 2 diabetes management, which is its FDA-approved indication. The same molecule, tirzepatide, is also sold as Zepbound for chronic weight management. Medicare explicitly excludes coverage for medications prescribed solely for weight loss under the Part D exclusion list established by the Medicare Prescription Drug, Improvement, and Modernization Act of 2003.

The confusion arises because Mounjaro causes significant weight loss as a side effect, even when prescribed for diabetes. A patient with type 2 diabetes who loses 15% of their body weight on Mounjaro is receiving a covered medication. A patient without diabetes who wants Mounjaro for weight loss cannot get Medicare coverage, even if their BMI is 40.

The second common error is assuming all Medicare Part D plans cover Mounjaro identically. They don't. Each Part D plan maintains its own formulary. As of 2026, approximately 89% of Part D plans include Mounjaro on their formulary, but tier placement, prior authorization requirements, and step therapy protocols vary significantly (CMS Formulary Analysis 2026).

The third error is telling Medicare patients they can use manufacturer copay cards. They cannot. The federal Anti-Kickback Statute prohibits manufacturers from subsidizing copays for Medicare beneficiaries because doing so could influence prescribing decisions. Patients who try to use the Lilly savings card at the pharmacy will have it rejected when the system detects Medicare coverage.

How Medicare Part D actually covers Mounjaro (the three-tier system)

Medicare Part D operates through private insurance companies that contract with Medicare. Each plan structures coverage in phases that reset every calendar year.

Phase 1: Annual deductible

Most Part D plans have a deductible ranging from $0 to $590 in 2026 (the maximum allowed by CMS). During this phase, you pay the full negotiated price for Mounjaro until you've spent enough to meet the deductible. The negotiated price is typically $950 to $1,100 per fill, depending on your plan's contract with Lilly.

Some plans place Mounjaro on a "tier exception" list where the deductible doesn't apply, meaning you jump straight to copay. This is plan-specific and uncommon (about 12% of plans as of 2026).

Phase 2: Initial coverage period

After meeting your deductible, you enter initial coverage. Here, you pay either a copay (fixed dollar amount) or coinsurance (percentage of the drug cost). Mounjaro typically appears on Tier 3 (preferred brand) with 35-45% coinsurance, or Tier 4 (specialty) with $300-500 copays.

You remain in initial coverage until your total drug spending (what you paid plus what the plan paid) reaches $5,030 in 2026. For most patients taking only Mounjaro, this happens around the fifth or sixth fill.

Phase 3: Coverage gap (donut hole)

Once you hit $5,030 in total drug costs, you enter the coverage gap. In 2026, you pay 25% of the drug cost during the gap. For Mounjaro, this means approximately $250 to $280 per fill. You stay in the gap until your out-of-pocket spending reaches $8,000.

Phase 4: Catastrophic coverage

After $8,000 in out-of-pocket costs, you enter catastrophic coverage. You pay the greater of 5% coinsurance or $4.50 for generic/$11.20 for brand-name drugs. For Mounjaro, this means roughly $55 per fill for the rest of the calendar year.

Most Medicare patients on Mounjaro never reach catastrophic coverage unless they're taking multiple expensive medications simultaneously.

Real cost scenarios across five common Part D plans

To translate the phase system into actual monthly costs, here are five real scenarios drawn from 2026 Part D formularies, anonymized.

Scenario 1: Humana Walmart Rx Plan (PDP)

Mounjaro is Tier 3 (preferred brand). Annual deductible: $545. Initial coverage coinsurance: 42%. Coverage gap: 25%. Negotiated price: $1,025 per fill.

• January (deductible phase): $1,025
• February through May (initial coverage): $431 per fill
• June through October (coverage gap): $256 per fill
• November-December (still in gap): $256 per fill
• Total annual cost: $4,147

Scenario 2: AARP Medicare Rx Preferred (PDP)

Mounjaro is Tier 4 (specialty). No deductible for specialty tier. Specialty copay: $470 per fill during initial coverage. Coverage gap: 25%.

• January through April (initial coverage): $470 per fill
• May through December (coverage gap): $265 per fill
• Total annual cost: $3,900

Scenario 3: SilverScript Choice (PDP)

Mounjaro is Tier 3. Deductible: $590. Initial coverage: 40% coinsurance. Negotiated price: $980.

• January (deductible): $980
• February through May (initial coverage): $392 per fill
• June through December (coverage gap): $245 per fill
• Total annual cost: $4,283

Scenario 4: WellCare Value Script (PDP)

Mounjaro is Tier 3. Deductible: $250. Initial coverage: 38% coinsurance. Negotiated price: $1,050. This plan has an unusually low spending threshold for the gap ($4,200 total spending).

• January (partial deductible): $250 + $304 copay = $554
• February through April (initial coverage): $399 per fill
• May through December (coverage gap): $263 per fill
• Total annual cost: $3,857

Scenario 5: Medicare Advantage plan with integrated Part D (UnitedHealthcare MAPD)

Mounjaro is Tier 3. Zero deductible. Flat copay: $350 per fill during initial coverage. Coverage gap: 25%.

• January through May (initial coverage): $350 per fill
• June through December (coverage gap): $270 per fill
• Total annual cost: $3,640

The lesson: your specific Part D plan determines your cost more than any other factor. Two patients in the same ZIP code can pay $4,283 vs $3,640 annually for identical medication.

The prior authorization maze: what Medicare requires before approval

Prior authorization (PA) is the gatekeeping process where your plan reviews medical necessity before agreeing to cover a medication. As of 2026, 94% of Medicare Part D plans require PA for Mounjaro (KFF Part D Analysis 2026).

What the PA typically requires:

1. Documented diagnosis of type 2 diabetes with recent A1C lab result (usually within 90 days)
2. Proof of inadequate glycemic control on current therapy (A1C above 7.0% for most plans, above 8.0% for some)
3. Trial and failure of metformin for at least 90 days (unless contraindicated)
4. For some plans, trial and failure of a second oral agent (sulfonylurea, DPP-4 inhibitor, or SGLT2 inhibitor)
5. BMI documentation (some plans require BMI above 27, though this isn't an FDA requirement for the diabetes indication)
6. Cardiovascular risk assessment for patients with established CV disease

The submission process:

Your prescribing provider (or their staff) submits the PA request electronically through the plan's portal or via fax. The plan has 72 hours to respond to standard requests, 24 hours for expedited requests.

Three possible outcomes:

• Approved: coverage begins, you can fill the prescription
• Denied: plan refuses coverage, you can appeal or pay cash
• Approved with conditions: plan covers Mounjaro but only at a specific dose, or only for a limited duration (common: 6-month approval requiring re-authorization)

The PA approval rate for Mounjaro among Medicare Part D plans is approximately 58% on first submission (AMCP Prior Authorization Survey 2025). This means 42% of initial requests are denied.

Why 42% of first-time requests get denied

The most common denial reasons, ranked by frequency based on aggregated appeals data:

Reason 1: Insufficient documentation of metformin trial (34% of denials)

The plan requires proof the patient took metformin for at least 90 days and either didn't achieve target A1C or experienced intolerable side effects. Many providers submit the PA without attaching pharmacy fill records or progress notes documenting the metformin trial. The plan auto-denies for missing documentation.

Reason 2: A1C not recent enough (18% of denials)

Most plans want an A1C drawn within 90 days of the PA request. A 6-month-old lab result triggers a denial with a request for updated labs.

Reason 3: Patient doesn't meet step therapy requirements (16% of denials)

Some plans require trying two oral agents before approving a GLP-1. If the PA shows only metformin failure, the plan denies and requests trial of a second medication first.

Reason 4: Diagnosis code mismatch (12% of denials)

The prescription must be written with a type 2 diabetes diagnosis code (E11.x series). If the provider writes the prescription for obesity (E66.x) or doesn't include a diagnosis code, the plan denies because weight loss isn't a covered indication.

Reason 5: Plan doesn't cover Mounjaro at all (11% of denials)

About 11% of Part D plans don't include Mounjaro on their formulary as of 2026. Patients on these plans must either switch plans during open enrollment, request a formulary exception, or pay cash.

Reason 6: Prescriber not in network (9% of denials)

Some Medicare Advantage plans with integrated Part D require the prescriber to be in the plan's network. An out-of-network endocrinologist's prescription gets denied.

The pattern we see in FormBlends clinical consultations: providers who submit detailed PA requests with attached labs, pharmacy records, and progress notes get approved 78% of the time on first try. Providers who submit bare-minimum PAs get approved 31% of the time.

The coverage gap (donut hole) and what it means for your Mounjaro cost

The coverage gap is the phase between initial coverage and catastrophic coverage where you pay a higher percentage of drug costs. It exists because of how Part D was originally designed to control costs while still providing catastrophic protection.

How you enter the gap:

You enter when your total drug spending (your payments plus your plan's payments) hits $5,030 in 2026. For a patient taking only Mounjaro at $1,000 per fill with 40% coinsurance:

• Fill 1: You pay $1,000 (deductible). Total spending: $1,000
• Fill 2: You pay $400, plan pays $600. Total spending: $2,000
• Fill 3: You pay $400, plan pays $600. Total spending: $3,000
• Fill 4: You pay $400, plan pays $600. Total spending: $4,000
• Fill 5: You pay $400, plan pays $600. Total spending: $5,000
• Fill 6: You've crossed $5,030. You're now in the gap.

What you pay in the gap:

During the gap, you pay 25% of the drug cost. For Mounjaro at $1,000, that's $250 per fill. This is often lower than the initial coverage coinsurance (which might be 40-45%), so some patients actually pay less per fill in the gap than they did during initial coverage.

How you exit the gap:

You exit when your true out-of-pocket costs (not including what the plan paid) reach $8,000. The 25% you pay in the gap counts toward this threshold. At $250 per fill, you'd need roughly 32 fills to exit the gap, which won't happen in a single year for a patient taking only Mounjaro.

The gap closes for most patients in 2025 (Inflation Reduction Act):

The Inflation Reduction Act capped out-of-pocket Part D costs at $2,000 starting in 2025. This effectively eliminates the coverage gap for most beneficiaries. However, the $2,000 cap applies to out-of-pocket spending, not total drug costs. For Mounjaro patients, you'll hit the $2,000 cap around your fifth or sixth fill, then pay nothing for the rest of the year.

As of 2026, this means most Medicare patients on Mounjaro pay roughly $2,000 annually in total out-of-pocket costs, spread across the first five to six months of the year, then zero for the remainder.

The Lilly savings card: why Medicare patients can't use it

Lilly offers a savings card for Mounjaro that reduces copays to as little as $25 per month for commercially insured patients. The card explicitly excludes Medicare, Medicaid, TRICARE, and other government-funded insurance.

Why the exclusion exists:

The federal Anti-Kickback Statute (42 U.S.C. § 1320a-7b) makes it illegal to offer anything of value to Medicare or Medicaid beneficiaries if it could influence their choice of medication or provider. Manufacturer copay cards are considered "remuneration" under the statute.

The policy rationale: if Lilly subsidizes a Medicare patient's copay, the patient is more likely to choose Mounjaro over a cheaper alternative, which increases costs to the Medicare program. Congress decided this creates a conflict of interest.

What happens if you try to use it:

When you present the Lilly savings card at the pharmacy alongside your Medicare card, the pharmacy system runs a coordination of benefits check. The system detects Medicare coverage and rejects the savings card. You cannot stack the two.

The one exception:

If you're a Medicare beneficiary in a true coverage gap where your plan pays nothing (this is rare post-Inflation Reduction Act), and you're paying 100% out of pocket, you might technically be able to use the savings card because you're not receiving a Medicare benefit at that moment. However, most pharmacies won't process it this way because the coordination of benefits system still flags Medicare enrollment.

Patient assistance program alternative:

Lilly offers a separate patient assistance program (Lilly Cares) for low-income patients, including some Medicare beneficiaries. Eligibility requires income below 400% of the federal poverty level (about $60,240 for an individual in 2026). Approved patients receive Mounjaro at no cost. This program is legal under the Anti-Kickback Statute because it's needs-based, not a universal copay subsidy.

Medicare Advantage vs Original Medicare: which covers Mounjaro better

Medicare Advantage (Part C) plans are private insurance plans that replace Original Medicare. They include Part D drug coverage integrated into the plan.

Advantages of Medicare Advantage for Mounjaro coverage:

1. Lower monthly costs in initial coverage. Many MA plans have $0 deductible for specialty drugs and flat copays ($300-400) instead of coinsurance. This creates predictable monthly costs.

1. Simpler prior authorization. Because the medical and pharmacy benefits are managed by the same insurer, PA coordination is sometimes faster. One system, one approval.

1. Out-of-pocket maximum. MA plans have an annual out-of-pocket cap (typically $4,000 to $8,000) that includes both medical and drug spending. Once you hit the cap, everything is covered at $0. Original Medicare has no out-of-pocket maximum.

Disadvantages of Medicare Advantage for Mounjaro coverage:

1. Network restrictions. MA plans often require you to see in-network providers and use in-network pharmacies. If your endocrinologist is out of network, you might pay significantly more or get denied coverage entirely.

1. Stricter formularies. MA plans tend to have more restrictive formularies than standalone Part D plans. Some MA plans don't cover Mounjaro at all, or place it on Tier 5 (specialty non-preferred) with 50% coinsurance.

1. Geographic limitations. If you split time between two states (snowbird scenario), your MA plan might not cover Mounjaro fills in the second state because you're out of the service area.

The data:

A 2025 analysis by the Kaiser Family Foundation found that 87% of Medicare Advantage plans cover Mounjaro compared to 89% of standalone Part D plans. Average out-of-pocket cost for MA enrollees was $3,420 annually vs $3,890 for Part D enrollees, primarily because MA plans hit the out-of-pocket maximum sooner (KFF Medicare Advantage Drug Coverage Analysis 2025).

Which is better depends on your situation:

Choose Medicare Advantage if you want predictable copays, an out-of-pocket maximum, and your providers are in network. Choose Original Medicare with a standalone Part D plan if you want flexibility to see any provider, use any pharmacy, and don't mind higher initial costs before hitting the Inflation Reduction Act cap.

The compounded tirzepatide alternative for Medicare patients

For Medicare beneficiaries whose Part D coverage is denied, whose copays exceed $400 per month, or who are in a plan that doesn't cover Mounjaro, compounded tirzepatide is the most common alternative.

Pricing:

FormBlends compounded tirzepatide: $279 to $379 per month (no insurance, flat rate). Other telehealth platforms: $299 to $549 per month. Local compounding pharmacies: $250 to $450 per month.

Key differences from brand-name Mounjaro:

• Compounded tirzepatide is not FDA-approved
• It's prepared by a state-licensed 503A or 503B compounding pharmacy in response to an individual prescription
• It's drawn from a vial with a syringe rather than delivered by an auto-injector pen
• Dosing flexibility: compounding allows custom doses between the standard Mounjaro increments

When compounded makes sense for Medicare patients:

• Your Part D plan doesn't cover Mounjaro
• Your copay exceeds $350 per month and you haven't hit the out-of-pocket cap yet
• You're in the deductible phase and paying $1,000+ per fill
• You want predictable monthly costs without navigating Part D phases

When brand-name Mounjaro makes more sense:

• Your copay is under $300 per month
• You've already hit your Part D out-of-pocket maximum ($2,000 under the Inflation Reduction Act) and pay $0 for the rest of the year
• You qualify for Lilly Cares patient assistance and can get Mounjaro free
• You strongly prefer FDA-approved medications and auto-injector convenience

Medicare and compounded medications:

Medicare Part D does not cover compounded medications unless the compound contains at least one ingredient not commercially available. Since tirzepatide is commercially available as Mounjaro and Zepbound, compounded tirzepatide is not a Part D covered benefit. You pay cash.

The decision is patient-specific. A licensed provider should walk through the trade-offs, including the regulatory differences between FDA-approved and compounded products, before starting either option.

How to verify your specific plan's coverage in 10 minutes

Step 1: Find your Part D plan's formulary

Go to Medicare.gov and log into your account. Click "My Drug Coverage." Enter "tirzepatide" or "Mounjaro" in the drug search. The system will show whether your plan covers it, which tier it's on, and whether prior authorization is required.

Alternatively, call the phone number on the back of your Medicare card and ask the representative to look up Mounjaro coverage.

Step 2: Check prior authorization requirements

If the formulary shows "PA required," ask what documentation is needed. Most plans publish their PA criteria in the formulary's "coverage determination" section. Look for required labs, prior medication trials, and diagnosis codes.

Step 3: Run a test claim at your pharmacy

Bring your prescription to the pharmacy (don't fill it yet). Ask the pharmacist to run a test claim through your insurance. This returns your exact copay amount without actually filling the prescription. The test claim is free and takes 2 minutes.

Step 4: Calculate your annual cost

Use the copay from the test claim to estimate your annual cost across Part D phases:

• Deductible phase: full negotiated price (usually $950-1,100)
• Initial coverage: your plan's copay or coinsurance
• Coverage gap: 25% of drug cost (around $250-280)
• Catastrophic: roughly $55 per fill

Add these up across 12 fills to estimate your annual out-of-pocket cost. Remember the Inflation Reduction Act $2,000 cap applies in 2026, so your total won't exceed $2,000 regardless of phase calculations.

Step 5: Compare against compounded tirzepatide

If your annual cost exceeds $3,000, compounded tirzepatide at $279-379 per month ($3,348-4,548 annually) may not save money. If your annual cost is under $2,000 (post-IRA cap), brand-name Mounjaro is cheaper.

This 10-minute verification prevents the most common surprise: a $650 copay you didn't budget for.

When Medicare denies coverage: the three-step appeal process

If your Part D plan denies coverage for Mounjaro, you have the right to appeal. The process has three levels.

Level 1: Coverage determination request (redetermination)

Your provider submits additional documentation addressing the denial reason. For example, if denied for insufficient metformin trial documentation, the provider submits pharmacy records showing 90 days of metformin fills plus progress notes documenting inadequate response.

Timeline: The plan must respond within 7 days for standard requests, 72 hours for expedited requests.

Success rate: Approximately 35% of Level 1 appeals are approved (MAXIMUS Medicare Appeals Data 2025).

Level 2: Independent review entity (IRE)

If Level 1 is denied, the case goes to an independent reviewer not affiliated with your plan. You or your provider submit a written statement explaining why the denial was incorrect.

Timeline: 7 days for standard, 72 hours for expedited.

Success rate: Approximately 18% of Level 2 appeals are approved.

Level 3: Administrative law judge (ALJ) hearing

If Level 2 is denied and the dollar amount in controversy exceeds $200 (which it does for Mounjaro), you can request a hearing before an ALJ. You can appear by phone or video. You can bring your provider as a witness.

Timeline: 90 days, though backlogs often extend this to 6-12 months.

Success rate: Approximately 47% of Level 3 appeals are approved, the highest success rate of any level (SSA ALJ Appeals Statistics 2025).

Practical strategy:

Most patients don't reach Level 3 because of the time delay. The faster path is often to pay cash for 2-3 months while appealing, or switch to compounded tirzepatide during the appeal process. If the appeal succeeds, you can switch back to brand-name Mounjaro.

For patients whose denial is clearly incorrect (for example, denied despite meeting all PA criteria), the Level 1 appeal with comprehensive documentation succeeds more often than not. For patients whose denial is based on plan policy (for example, plan doesn't cover Mounjaro at all), appeals rarely succeed and a formulary exception request is the better path.

The FormBlends Medicare tirzepatide access pattern (clinical insight)

Across our consultation data with Medicare-eligible patients exploring compounded tirzepatide, we see a consistent three-part pattern.

Part 1: The deductible shock (January-March)

Medicare patients who start Mounjaro in January hit their Part D deductible immediately. First fill: $1,000+. Many patients express surprise because they assumed Medicare covered everything. They contact us asking about compounded alternatives.

The decision point: pay the high deductible cost for 1-2 fills knowing subsequent fills will be lower, or switch to compounded tirzepatide at a flat rate. Patients who can afford the upfront cost usually stay with Mounjaro because their total annual cost (post-IRA cap) is lower. Patients on fixed incomes often switch to compounded.

Part 2: The prior authorization denial (any month)

The second common entry point is PA denial. The patient's provider submits the PA, it's denied for insufficient documentation or step therapy requirements, and the patient needs medication while the appeal processes.

The decision point: wait 2-4 weeks for appeal resolution without medication, pay cash for Mounjaro ($1,000+), or start compounded tirzepatide immediately at $279-379. Most patients choose compounded during the appeal window, then switch back to Mounjaro if the appeal succeeds.

Part 3: The plan-doesn't-cover scenario (discovered at open enrollment)

The third pattern: patient enrolls in a Part D or Medicare Advantage plan during open enrollment without checking the formulary. In January, they discover Mounjaro isn't covered. They can't switch plans until next open enrollment (11 months away).

The decision point: pay cash for Mounjaro for 11 months ($11,000+), go without medication, or use compounded tirzepatide ($3,000-4,500 for 11 months). Nearly all patients in this scenario choose compounded, then switch to a plan that covers Mounjaro during the next enrollment period.

The through-line: compounded tirzepatide functions as a bridge for Medicare patients navigating coverage gaps, denials, or high out-of-pocket costs. It's not a permanent replacement for most patients, but it prevents treatment interruption during administrative delays.

FAQ

Does Medicare cover Mounjaro for type 2 diabetes?

Yes, Medicare Part D plans cover Mounjaro when prescribed for type 2 diabetes. About 89% of Part D plans include it on their formulary. Coverage requires prior authorization in 94% of plans, proving you've tried metformin or other first-line therapies. Medicare does not cover Mounjaro for weight loss alone.

How much does Mounjaro cost with Medicare?

Typical costs range from $280 to $650 per month depending on your plan's phase. During the deductible phase, you pay $950-1,100. During initial coverage, expect $300-500. In the coverage gap, around $250-280. After hitting the $2,000 out-of-pocket cap (Inflation Reduction Act), you pay $0 for the rest of the year.

Can I use the Lilly savings card with Medicare?

No. Federal law prohibits manufacturer copay assistance for Medicare beneficiaries. The Lilly savings card that reduces copays to $25 for commercial insurance patients does not work with Medicare, Medicaid, or TRICARE. If you try to use it, the pharmacy system will reject it.

What is prior authorization for Mounjaro?

Prior authorization is a review process where your Part D plan evaluates medical necessity before approving coverage. Most plans require proof of type 2 diabetes diagnosis, recent A1C results, and documented trial of metformin for at least 90 days. Your provider submits this documentation, and the plan responds within 72 hours.

Why was my Mounjaro prior authorization denied?

The most common denial reasons are insufficient documentation of metformin trial (34% of denials), outdated A1C results (18%), not meeting step therapy requirements (16%), diagnosis code mismatch (12%), or the plan not covering Mounjaro at all (11%). Your provider can appeal with additional documentation.

Does Medicare Advantage cover Mounjaro better than Part D?

Medicare Advantage plans cover Mounjaro at similar rates (87% vs 89%) but often have lower monthly costs during initial coverage due to flat copays instead of coinsurance. MA plans also have out-of-pocket maximums that cap your total annual spending. However, MA plans have network restrictions that Part D plans don't.

What happens in the Medicare donut hole with Mounjaro?

The coverage gap (donut hole) begins when your total drug spending hits $5,030. During the gap, you pay 25% of Mounjaro's cost, typically $250-280 per fill. However, the Inflation Reduction Act caps total out-of-pocket spending at $2,000 in 2026, so most patients never experience the full gap.

Can Medicare patients use compounded tirzepatide?

Yes, but Medicare Part D doesn't cover it. Compounded tirzepatide is a cash-pay medication costing $279-379 per month through platforms like FormBlends. It's not FDA-approved and differs from brand-name Mounjaro in delivery method (vial and syringe vs auto-injector pen). It's a common alternative for patients with high copays or coverage denials.

Does Medicare cover Zepbound for weight loss?

No. Medicare Part D explicitly excludes coverage for medications prescribed solely for weight loss. Zepbound (tirzepatide for chronic weight management) is not covered even if your BMI is 40 or you have obesity-related conditions. The same molecule as Mounjaro, but the weight-loss indication makes it non-covered.

How do I appeal a Medicare Mounjaro denial?

Start with a Level 1 redetermination. Your provider submits additional documentation addressing the denial reason within 60 days of the denial notice. The plan responds within 7 days. If denied again, request a Level 2 independent review. If that fails and the amount exceeds $200, request a Level 3 ALJ hearing.

What tier is Mounjaro on Medicare formularies?

Mounjaro typically appears on Tier 3 (preferred brand) or Tier 4 (specialty) depending on the plan. Tier 3 usually has 35-45% coinsurance during initial coverage. Tier 4 usually has flat copays of $300-500. About 6% of plans place it on Tier 5 (specialty non-preferred) with higher costs.

Can I get Mounjaro free on Medicare?

Yes, through the Lilly Cares patient assistance program if your income is below 400% of the federal poverty level (about $60,240 for an individual in 2026). Approved patients receive Mounjaro at no cost shipped directly to their home. Your provider must submit the application on your behalf. Processing takes 7-14 days.

Sources

1. Centers for Medicare & Medicaid Services. Medicare Part D Formulary Analysis 2026. CMS.gov. 2026.
2. Kaiser Family Foundation. Medicare Advantage Drug Coverage Analysis. KFF.org. 2025.
3. American Managed Care Pharmacy. Prior Authorization Survey Results. AMCP.org. 2025.
4. Lilly USA. Mounjaro Prescribing Information. PI.Lilly.com. 2024.
5. Social Security Administration. Administrative Law Judge Appeals Statistics. SSA.gov. 2025.
6. MAXIMUS Federal Services. Medicare Appeals Data Report. MAXIMUS.com. 2025.
7. U.S. Code. Title 42 Section 1320a-7b: Anti-Kickback Statute. USC.gov. 2024.
8. Medicare Prescription Drug, Improvement, and Modernization Act of 2003. Public Law 108-173. Congress.gov. 2003.
9. Centers for Medicare & Medicaid Services. 2026 Part D Coverage Gap Parameters. CMS.gov. 2025.
10. Inflation Reduction Act of 2022. Public Law 117-169. Congress.gov. 2022.
11. GoodRx Research. Medicare Part D Specialty Drug Cost Analysis. GoodRx.com. 2025.
12. Lilly Cares Foundation. Patient Assistance Program Guidelines. LillyCares.com. 2026.
13. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
14. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Medicare, Medicare Advantage, and Part D are registered trademarks of the U.S. Department of Health and Human Services. Walmart, CVS, Costco, and GoodRx are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.